Ruboxistaurin

Ruboxistaurin
Clinical data


ATC code	none
Identifiers
IUPAC name (9S)-9-[(dimethylamino)methyl]-6,7,10,11-tetrahydro-9H,18H-5,21:12,17-di(metheno)dibenzo[e,k]pyrrolo[3,4-h][1,4,13]oxadiazacyclohexadecine-18,20-dione
CAS Number	169939-94-0^N
PubChem (CID)	153999
IUPHAR/BPS	5263
ChemSpider	135727^Y
UNII	721809WQCP^Y
ChEMBL	CHEMBL91829^Y
Chemical and physical data
Formula	C₂₈H₂₈N₄O₃
Molar mass	468.546 g/mol
InChI InChI=1S/C28H28N4O3/c1-30(2)15-18-11-12-31-16-21(19-7-3-5-9-23(19)31)25-26(28(34)29-27(25)33)22-17-32(13-14-35-18)24-10-6-4-8-20(22)24/h3-10,16-18H,11-15H2,1-2H3,(H,29,33,34)/t18-/m0/s1^Y Key:ZCBUQCWBWNUWSU-SFHVURJKSA-N^Y
^NY (what is this?) (verify)

Ruboxistaurin (proposed brand name Arxxant) is an investigational drug for diabetic peripheral retinopathy being investigated by Eli Lilly and Company. It is a member of the bisindolylmaleimide family.

On February 2006, Lilly submitted a New Drug Application for ruboxistaurin, and on August 18, 2006, Lilly received an "approvable" letter from the United States Food and Drug Administration for ruboxistaurin,^[1] with a request for an additional clinical trial, which would take 5 years to complete.^[2]

Mechanism of action

Ruboxistaurin is an inhibitor of protein kinase C-beta.^[3]

References

↑ "Drugs.com, Eli Lilly and Company Announces Approvable Letter Issued by FDA for Arxxant". Retrieved 2008-02-15.
↑ "Drugs.com, Lilly Announces FDA Requirement of Additional Clinical Trial Before Ruboxistaurin Could Be Approved for Treatment of Diabetic Retinopathy". Retrieved 2008-02-15.
↑ Clarke M, Dodson PM (December 2007). "PKC inhibition and diabetic microvascular complications". Best Pract Res Clin Endocrinol Metab. 21 (4): 573–86. doi:10.1016/j.beem.2007.09.007. PMID 18054736.

External links

Eli Lilly and Company Product Pipeline

This article is issued from Wikipedia - version of the 9/14/2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.